TITLE

Intracerebral hemorrhage: natural history and rationale of ultra-early hemostatic therapy

AUTHOR(S)
Mayer, Stephan A.
PUB. DATE
October 2002
SOURCE
Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS235
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Stroke is a major health problem worldwide, causing high morbidity and mortality. Intracerebral hemorrhage (ICH) accounts for 15% of stroke cases in the US and Europe and up to 30% in Asian populations. It is less treatable than other forms of stroke and causes higher morbidity and disability. Data suggest that early hematomy growth is the principal cause of early neurological deterioration after ICH. Prospective and retrospective studies indicate that early hematoma growth occurs in 18-38% of patients scanned within 3 h of ICH onset, and that hematoma volume is an important predictor of 30-day mortality. As hematoma growth in acute ICH is a dynamic process, intervention with ultra-early hemostatic therapy could lead to minimization and even prevention of early hematomy growth. Recombinant activated factor VII (rFVIIa, 'NovoSeven'), a powerful initiator of hemostasis, is approved for the treatment of bleeding in patients with hemophilia and inhibitors and may also promote hemostasis in patients with normal coagulation. rFVa acts locally at the bleeding site without activating systemic coagulation and may be a valuable therapy during the hyperacute stage of ICH. A randomized, double-blind, placebo-controlled, dose-ranging trial is currently in progress to investigate the potential of rFVIIa as an ultra-early hemostatic therapy to prevent or minimize hematoma growth in ICH patients without coagulopathy.
ACCESSION #
15729756

 

Related Articles

  • Ongoing NovoSeven trials. Erhardtsen, Elisabeth // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS248 

    Recombinant activated factor VII (rFVIIa, 'NovoSeven' was initially developed for the treatment of bleeding in patients with haemophilia and inhibitors, and is currently licensed in most countries worldwide. The mechanism of action suggests that its enhancing effects in haemostasis are limited...

  • Updates in the management of severe coagulopathy in trauma patients. Lynn, Mauricio; Jeroukhimov, Igor; Klein, Yoram; Martinowitz, Uri // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS241 

    Coagulopathy is the major cause of bleeding-related mortality in patients who survive the operating room. Its association with hypothermia and metabolic acidosis is common and constitutes a vicious cycle. Usually, post-traumatic coagulopathy is an early event and may be present during surgery....

  • Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII? Kessler, Craig // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS228 

    Recombinant activated factor VII (rFVIIa, 'NovoSeven') is indicated for the treatment of bleeding in patients with haemophilia and inhibitors to factors VIII or IX. However, by virtue of its ability to promote thrombin generation on the platelet surface rFVIIa may also be effective in...

  • Factor V Leiden Mutation in Cerebrovascular Disease. Buyru, Nur; Altinisik, Julide; Somay, Goksel; Ulutin, Turgut // Clinical & Applied Thrombosis/Hemostasis;Jul2005, Vol. 11 Issue 3, p339 

    Several studies indicate a high prevalence of factor V Leiden mutation as the most frequent coagulation defect found in patients with venous thrombosis. The relationship between this mutation and cerebrovascular disease has not been established in adults. In this investigation, we studied 29...

  • Treatment of intracerebral hemorrhage: lessons from recent studies. Strupp, Michael // Journal of Neurology;Apr2005, Vol. 252 Issue 4, p502 

    Discusses the study "Stopping the bleeding in intracerebral hemorrhage," by D.L. Brown and L.B. Morgenstern, published in the "New England Journal of Medicine." Comparison between early surgery and initial conservative treatment; Evidence that recombinant activated factor VII improves the...

  • NovoSeven: mode of action and use in acquired haemophilia. von Depka, Mario // Intensive Care Medicine;Oct2002 Supplement 2, Vol. 28, pS222 

    Recombinant activated factor VII (rFVIIa, 'NovoSeven') is indicated for the treatment of spontaneous and surgical bleeding in patients with haemophilia A or B with antibodies to factors VIII or IX (FVIII or FIX) worldwide, and in patients with acquired haemophilia in Europe. In vitro cell models...

  • Recombinant Factor VIIa (Eptacog Alfa): A Review of its Use in Congenital or Acquired Haemophilia and Other Congenital Bleeding Disorders. Siddiqui, M. Asif A.; Scott, Lesley J. // Drugs;2005, Vol. 65 Issue 8, p1161 

    Recombinant factor VIIa (NovoSeven®) [also known as recombinant activated factor VII or eptacog alfa] is a vitamin K-dependent glycoprotein that is structurally similar to human plasma-derived factor VIIa. It is a recombinant product, manufactured using DNA biotechnology. Intravenous...

  • Recombinant factor VIIa use in patients with the rarest forms of inherited coagulation-factor deficiencies: a study of cases from the www.haemostasis.com registry. Smejkal, P.; Hassan, M.; Ingerslev, J. // Comparative Clinical Pathology;Dec2006, Vol. 15 Issue 4, p203 

    Rare inherited coagulation disorders (RICDs) with a prevalence of ≤1/1,000,000 include deficiencies in factor II, factor V, combined factor V/factor VIII, factor X, factor XI and factor XIII. These abnormalities are associated with spontaneous haemorrhage and excessive bleeding after...

  • Octocog alfa, Plasma/Albumin-Free Method: A Viewpoint by Jørgen Ingerslev. Ingerslev, Jørgen // Drugs;2005, Vol. 65 Issue 18, p2621 

    This article focuses on role of coagulation factor VIII in the management of bleeding episodes in patients with classic congenital hemophilia. New recombinant factor VIII concentrates were seen as a major safety advantage for recipients. The concentrates were utilized as cell-line nutrients...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics